Compare Sanofi SA (SNY) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Under Armour Inc Class A — how do they compare? Sanofi SA trades at $43.6 (market cap $104.30B), while Under Armour Inc Class A trades at $5.16 (market cap $2.26B). The key difference: Sanofi SA is far larger — about 46.2× Under Armour Inc Class A's market cap, and Sanofi SA pays a 5.55% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| SNY | UA | |
|---|---|---|
Market Cap | $104.30B | $2.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $52.34 | $7.88 |
52-Week Low | $41.33 | $3.96 |
Enterprise Value | $124.19B | $3.24B |
Dividend Yield | 5.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Under Armour (UA) trades at $5.20, down 8.37% amid weak quarterly results and lowered revenue guidance. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal declining revenue ($5.16B in 2025 to $4.9B in 2026) and negative profitability (net margin -9.99%). Recent news highlights softer consumer demand in key markets, though the company maintains its profitability outlook.
The outlook remains challenging with significant execution risks and competitive pressures. While analyst sentiment is mixed (38.81% Buy, 49.25% Hold), the stock's deep value metrics (P/S 0.45) may attract contrarian investors if operational improvements materialize. Key risks include sustained revenue declines and negative cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
